We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

CERENIS Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease

News   May 16, 2008

 
CERENIS Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
 
 
Advertisement
 

RELATED ARTICLES

Scientists Develop the First Known Methyl Transferase Ribozyme

News

The research group of chemistry professor Claudia Höbartner is now reporting a scientific breakthrough: Her team at Julius-Maximilians-Universität Würzburg (JMU) in Bavaria, Germany, has developed a ribozyme that can attach a very specific small chemical change at a very specific location in a target RNA.

READ MORE

Biomarkers Could Be Used in Quick COVID-19 Blood Screening Strategy

News

A new study suggests that COVID-19 affects the human body’s blood concentration levels of specific metabolites. Three metabolites identified in the study could act as biomarkers and hold potential to be measured through an inexpensive blood test to quickly screen patients for the disease.

READ MORE

Avoiding Side Effects Associated With Cancer Treatment

News

Researchers at the University of California, Irvine and Switzerland's Lausanne University Hospital/University of Lausanne (CHUV/UNIL) may have found a way to treat cancer without the onset of debilitating side effects.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE